Search hospitals
>
New York
>
New York
Columbia University Irving Medical Center
Claim this profile
New York, New York 10032
Global Leader in Cancer
Global Leader in Pancreatic Cancer
Conducts research for Lung Cancer
Conducts research for Solid Tumors
Conducts research for I Am A Healthy Volunteer
358 reported clinical trials
122 medical researchers
Summary
Columbia University Irving Medical Center is a medical facility located in New York, New York. This center is recognized for care of Cancer, Pancreatic Cancer, Lung Cancer, Solid Tumors, I Am A Healthy Volunteer and other specialties. Columbia University Irving Medical Center is involved with conducting 358 clinical trials across 814 conditions. There are 122 research doctors associated with this hospital, such as Susheel Kodali, MD, Richard Carvajal, MD, Luca Szalontay, MD, and Ran Reshef, MD.
Area of expertise
Cancer
Columbia University Irving Medical Center has run 30 trials for Cancer. Some of their research focus areas include:
Pancreatic Cancer
Columbia University Irving Medical Center has run 28 trials for Pancreatic Cancer. Some of their research focus areas include:
Top PIs
Susheel Kodali, MD
Columbia University Medical Center/NYPH
7 years of reported clinical research
Richard Carvajal, MD
Columbia University Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical Protoco
3 years of reported clinical research
Luca Szalontay, MD
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
8 years of reported clinical research
Ran Reshef, MD
Columbia University Irving Medical Center
4 years of reported clinical research
Clinical Trials running at Columbia University Irving Medical Center
Cancer
Breast Cancer
Lymphoma
Obesity
Ovarian Cancer
Lung Cancer
Endometrial Cancer
Spinal Muscular Atrophy
Alzheimer's Disease
Insulin Resistance
Abatacept
for Myocarditis
This Trial tests if abatacept can reduce serious heart problems in patients with heart inflammation caused by cancer treatments. Abatacept calms the immune system by preventing certain immune cells from becoming fully active, reducing inflammation and damage. Abatacept has been approved by the US Food and Drug Administration for the treatment of rheumatoid arthritis, with or without methotrexate.
Recruiting
3 awards
Phase 3
11 criteria
Emavusertib +/- Ibrutinib
for CNS Lymphoma
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated in combination with ibrutinib at 560 milligrams (mg) once daily (QD) or 420 mg QD as indicated by disease (Part A2 complete). Part B will comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in participants with R/R primary central nervous system lymphoma (PCNSL) who have directly progressed on a bruton tyrosine kinase inhibitor (BTKi). In this part of the study, emavusertib will be dosed at 100 mg or 200 mg twice daily (BID) in combination with ibrutinib in 28-day treatment cycles. Part C will comprise 3 treatment arms in the second-line setting to assess the efficacy and safety of emavusertib monotherapy, ibrutinib monotherapy, and emavusertib in combination with ibrutinib in participants with R/R PCNSL who are naïve to BTKi treatment. In this part of the study, eligible second-line participants with R/R PCNSL who are naïve to BTKi treatment will be randomized 1:1:1 to 1 of 3 treatment arms: (1) emavusertib 200 mg BID, (2) ibrutinib 560 mg QD, or (3) emavusertib 200 mg BID in combination with ibrutinib 560 mg QD.
Recruiting
1 award
Phase 1 & 2
1 criteria
Antibody-Drug Conjugate
for Advanced Cancer
This trial is testing MBRC-101, a new drug, in patients with advanced cancers that haven't improved with other treatments. It aims to find the best dose and check its safety and effectiveness. The study will also observe how the drug behaves in the body and if it causes any immune reactions.
Recruiting
1 award
Phase 1 & 2
16 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Columbia University Irving Medical Center?
Columbia University Irving Medical Center is a medical facility located in New York, New York. This center is recognized for care of Cancer, Pancreatic Cancer, Lung Cancer, Solid Tumors, I Am A Healthy Volunteer and other specialties. Columbia University Irving Medical Center is involved with conducting 358 clinical trials across 814 conditions. There are 122 research doctors associated with this hospital, such as Susheel Kodali, MD, Richard Carvajal, MD, Luca Szalontay, MD, and Ran Reshef, MD.
Where is Columbia University Irving Medical Center located?
The Columbia University Irving Medical Center is located at West 168th Street and Broadway in the Washington Heights neighborhood of northern Manhattan. For public transportation, options include the 1, A, or C trains to the 168th Street station, or buses M-2, 3, 4, 5, or 100. If driving, the recommended route involves exiting towards the George Washington Bridge, onto Riverside Drive, then left onto West 165th Street, and right onto Fort Washington Avenue to reach the medical center's parking facility.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Columbia University Irving Medical Center, contact the Office for Billing Compliance at 212-342-3947 or email shsinsurance@cumc.columbia.edu. For insurance inquiries, visit the Insurance and Administration department at 100 Haven Avenue, Tower 2, 2nd Floor, or email shsinsurance@cumc.columbia.edu.
What insurance does Columbia University Irving Medical Center accept?
The Columbia University Irving Medical Center (CUIMC) accepts a broad spectrum of insurance plans, including both commercial and government options. For specific doctor-related insurance inquiries, patients should refer to the doctor's profile on the ColumbiaDoctors website or contact the practice directly via phone as listed under "Our Locations." NewYork-Presbyterian Hospital, affiliated with CUIMC, supports a variety of insurance plans such as Aetna, Blue Cross Blue Shield, Cigna, United Healthcare, among others. Patients are advised to confirm with their insurance company to ensure coverage.
What awards or recognition has Columbia University Irving Medical Center received?
Columbia University Irving Medical Center (CUIMC) is celebrated for its pioneering research and superior patient care. It has been acknowledged for significant medical milestones, including the first successful heart transplant in a child and the development of the Apgar score for newborn assessment. CUIMC's faculty have received top honors, including the Nobel Prize in Chemistry, underscoring its dedication to scientific excellence and innovation.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.